Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTRACK
2022-501322-38-00Phase 2Suspended
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tiragolumab and atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Major pathological response rate after curative-intent surgery. Started May 2023; status: suspended.
02
Drugs
tiragolumabatezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-501322-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501322-38-00.